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Sterile or non-sterile gloves 
for minor skin excisions?
Non-sterile gloves are just as effective as sterile gloves 
in preventing surgical site infection after minor skin 
surgeries.
Would you  
consider using 
non-sterile gloves 
for a minor skin 
excision? 
n	 	Yes
n	 	No
n			Only if the 
procedure did not 
involve sutures
insTanT  
poll
jfponline.com
PRACTICE CHANGER
Consider using non-sterile gloves during mi-
nor skin excisions (even those that require 
sutures) because the infection rate is not in-
creased compared to using sterile gloves.1
StReNGtH OF ReCOMMeNDAtiON
B: Based on a randomized controlled trial 
done in a primary care practice.
Heal C, Sriharan S, Buttner PG, et al. Comparing non-sterile to sterile 
gloves for minor surgery: a prospective randomized controlled non-
inferiority trial. Med	J	Aust. 2015;202:27-31.
ILLUSTRATIVE CASE
a 50-year-old man comes to your office to 
have a mole removed from his arm. you de-
cide to excise the lesion in your office today. 
Do you need to use sterile gloves for this pro-
cedure, or can you use gloves from the clean 
non-sterile box in the exam room?
Non-sterile gloves are readily avail-able during a typical office visit and cost up to a dollar less per pair than 
sterile gloves.1-3 Studies conducted in settings 
other than primary care offices have shown 
that non-sterile gloves do not increase the 
risk of infection during several types of minor 
skin procedures. 
A partially blinded, randomized con-
trolled trial (RCT) in an emergency depart-
ment found no significant difference in 
infection rates between the use of sterile 
(6.1%) vs non-sterile (4.4%) gloves during 
laceration repairs.2 Similarly, a small RCT 
in an outpatient dermatology clinic and a 
larger prospective trial by a Mohs dermatolo-
gist showed that infection rates were not in-
creased after Mohs surgery using non-sterile 
(0.49%) vs sterile (0.50%) gloves.3,4 
Guidelines on the use of sterile vs non-
sterile gloves for minor skin excisions in out-
patient primary care are difficult to come by. 
Current guidelines from the Centers for Dis-
ease Control and Prevention (CDC) and oth-
er agencies regarding surgical site infections 
are broad and focus on the operating room 
environment.5-7 
The American Academy of Dermatol-
ogy is working on a guideline for treatment 
of non-melanoma skin cancer that’s due out 
this winter, and this may provide additional 
guidance.8 A 2003 review instructed primary 
care physicians to use sterile gloves for exci-
sional skin biopsies that require sutures.9
The 2015 study by Heal et al1 appears to be 
the first RCT to address the question of sterile 
vs non-sterile glove use for minor skin exci-
sions in a primary care outpatient practice.
STUDY SUMMARY
Non-sterile gloves  
are not inferior to sterile gloves 
Heal et al1 conducted a prospective, random-
ized, controlled, noninferiority trial to com-
pare the incidence of infection after minor 
skin surgery performed by 6 physicians from a 
single general practice in Australia using ster-
ile vs non-sterile clean gloves. They evaluated 
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576 consecutive patients who presented for 
skin excision between June 2012 and March 
2013. Eighty-three patients were excluded 
because they had a latex allergy, were using 
oral antibiotics or immunosuppressive drugs, 
or required a skin flap procedure or excision 
of a sebaceous cyst. The physicians followed 
a standard process for performing the proce-
dures and did not use topical antibiotics or 
antiseptic cleansing after the procedure. 
The primary outcome was surgical site 
infection within 30 days of the excision, de-
fined as purulent discharge, pain or tender-
ness, localized swelling or redness or heat at 
the site, or a diagnosis of skin or soft tissue 
infection by a general practitioner. The clini-
cians who assessed for infection were blind-
ed to the patient’s assignment to the sterile or 
non-sterile glove group, and a stitch abscess 
was not counted as an infection. 
The patients’ mean age was 65 years and 
59% were men. At baseline, there were no 
large differences between patients in the ster-
ile and non-sterile glove groups in terms of 
smoking status, anticoagulant or steroid use, 
diabetes, excision site, size of excision, and 
median days until removal of sutures. The le-
sions were identified histologically as nevus 
or seborrheic keratosis, skin cancer and pre-
cursor, or other.
The incidence of infection in the non-ster-
ile gloves group was 21/241 (8.7%; 95% confi-
dence interval [CI], 4.9%-12.6%) vs 22/237 in 
the control group (9.3%; 95% CI, 7.4%-11.1%). 
The CI (95%) for the difference in infection rate 
(-0.6%) was -4.0% to 2.9%. This was significantly 
below the predetermined noninferiority mar-
gin of 7%. In a sensitivity analysis of patients lost 
to follow-up (15 patients, 3%) that assumed all 
of these patients were without infection, or with 
infection, the CI was still below the noninferi-
ority margin of 7%. The per-protocol analysis 
showed similar results.
WHAT’S NEW
New evidence questions the need  
for sterile gloves for in-office excisions
Heal et al1 demonstrated that in a primary 
care setting, non-sterile gloves are not infe-
rior to sterile gloves for performing excisional 
procedures that require sutures. While stan-
dard practice has many family physicians 
using sterile gloves for these procedures, this 
study promotes changing this behavior. 
CAVEATS
A high infection rate, other factors  
might limit generalizability
The overall rate of infection in this study (9%) 
was higher than that found in the studies from 
emergency medicine and dermatology litera-
ture cited earlier.2-4 A similarly high infection 
rate has been found in other studies of minor 
surgery by Heal et al, including a 2006 study 
that showed a wound infection rate of 8.6%.10 
The significance of the higher infection rate 
is unknown, but there is no clear reason why 
non-sterile gloves might be less effective in 
preventing infection in environments with 
lower infection rates. 
This was not a double-blinded study, 
and physicians might change their behavior 
during a procedure depending on the type 
of gloves they are wearing. The sterile gloves 
used in this study contained powder, while 
the non-sterile gloves were powderless, but 
this variable is not known to affect infection 
rates. A study of Mohs surgery avoided this 
variable by only using powderless gloves, and 
had similar outcomes in terms of the differ-
ence in infection rate between sterile and 
non-sterile gloves.4 
CHALLENGES TO IMPLEMENTATION
ingrained habits can be  
hard to change
Tradition and training die hard. While mul-
tiple studies in several settings have found 
non-sterile gloves are non-inferior to sterile 
gloves in preventing surgical site infection 
after minor skin surgeries, this single study 
in the primary care office setting may not be 
enough to sway family physicians from in-
grained habits.                 JFP
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Table 1: Adverse Reactions Reported by at least 2% of Patients in Study 1
Adverse Reaction
Percent of Subjects Reporting
ZECUITY
(n = 234)
Control
(n = 235)
Application	site	pain
Application	site	paresthesia
Application	site	pruritus
Application	site	warmth
Application	site	discomfort
Application	site	irritation
Application	site	discoloration
26%
9%
8%
6%
6%
4%
3%
17%
16%
7%
3%
6%
2%
1%
The	 incidence	 of	 “atypical	 sensations”	 adverse	 events	 (paresthesia,	 sensation	
warm/cold)	and	“pain	and	other	pressure	sensations”	(chest	pain/tightness/pressure/
heaviness	or	neck/throat/jaw	pain,	tightness,	pressure	or	heaviness)	was	2%	each	in	
ZECUITY-treated	patients,	vs.	0%	in	the	control	group.	Application	site	bruising	was	
reported	in	2	ZECUITY-treated	patients	(0.9%)	vs.	no	patient	in	the	control	group.	
Subgroup	analyses	of	age	(≤41	years,	>41	years),	race	(Caucasian,	non-Caucasian)	
and	body	mass	index	(BMI)	(≤25.7	mg/kg2,	>25.7	mg/kg2)	showed	no	difference	
between	subgroups	for	adverse	events.
Skin Irritation Examination
In	Study	1,	patients	performed	their	own	examination	of	the	TDS	application	site	at	
4,	12,	and	24	hours	post	TDS	activation,	and	daily	thereafter	until	resolution.	The	
median	time	to	“no	redness”	was	2.6	days	for	ZECUITY	compared	with	0.3	day	in	
the	control	group.
Application site reactions across clinical studies (Controlled single dose acute 
migraine study and long term safety studies)
In	 the	 controlled	 and	 uncontrolled	 clinical	 studies	 combined	 (n	 = 796	 unique	 
ZECUITY-treated	 subjects),	 the	 frequency	 of	 application	 site	 reactions	 of	 clinical	
interest	was:	discoloration	(5%),	contact	dermatitis	(4%),	irritation	(4%),	vesicles 
(3%),	bruising	(2%),	and	erosion	(0.4%).
DRUG INTERACTIONS 
Ergot-Containing Drugs 
Ergot-containing	 drugs	 have	 been	 reported	 to	 cause	 prolonged	 vasospastic	 
reactions.	Because	these	effects	may	be	additive,	use	of	ergotamine-containing	or	
ergot-type	 medications	 (like	 dihydroergotamine	 or	 methysergide)	 and	 ZECUITY	
within	24	hours	of	each	other	is	contraindicated	[see Contraindications]. 
Monoamine Oxidase-A Inhibitors
MAO-A	 inhibitors	 increase	 systemic	 exposure	 by	 2-fold.	 Therefore,	 the	 use	 of	
ZECUITY	in	patients	receiving	MAO-A	inhibitors	is	contraindicated	[see Contrain-
dications].
Other 5-HT1 Agonists
Because	their	vasospastic	effects	may	be	additive,	coadministration	of	ZECUITY	and	
other	5-HT1	agonists	(e.g.,	triptans)	within	24	hours	of	each	other	is	contraindicated.
Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake 
Inhibitors and Serotonin Syndrome 
Cases	of	serotonin	syndrome	have	been	reported	during	coadministration	of	trip-
tans	and	SSRIs	or	SNRIs,	SNRIs,	TCAs,	and	MAO	 inhibitors	 [see Warnings and 
Precautions].
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy	Category	C:	There	are	no	adequate	and	well-controlled	studies	in	preg-
nant	women.	ZECUITY	should	be	used	during	pregnancy	only	if	the	potential	benefit	
justifies	the	potential	risk	to	the	fetus.
Nursing Mothers
It	is	not	known	whether	sumatriptan	is	excreted	in	human	milk	following	transder-
mal	administration.	Because	many	drugs	are	excreted	in	human	milk,	and	because	
of	the	potential	 for	serious	adverse	reactions	 in	nursing	infants	from	ZECUITY,	a	
decision	should	be	made	whether	to	discontinue	nursing	or	to	discontinue	the	drug,	
taking	into	account	the	importance	of	the	drug	to	the	mother.
Pediatric Use
Safety	and	effectiveness	in	pediatric	patients	have	not	been	established.	
Since	clinical	data	to	determine	the	frequency	of	serious	adverse	reactions	in	pedi-
atric	patients	who	might	receive	subcutaneous,	oral,	or	intranasal	sumatriptan	are	
not	presently	available,	the	use	of	ZECUITY	in	patients	under	18	years	of	age	is	not	
recommended.
Geriatric Use
Clinical	trials	of	ZECUITY	did	not	 include	sufficient	numbers	of	subjects	aged	65	
and	over	to	determine	whether	they	respond	differently	from	younger	subjects.	In	
general,	dose	selection	for	an	elderly	patient	should	be	cautious,	usually	starting	
at	the	low	end	of	the	dosing	range,	reflecting	the	greater	frequency	of	decreased	
hepatic,	renal,	or	cardiac	function	and	of	concomitant	disease	or	other	drug	therapy.	
A	 cardiovascular	 evaluation	 is	 recommended	 for	 geriatric	 patients	who	 have	 other	
cardiovascular	risk	factors	prior	to	using	ZECUITY	[see Warnings and Precautions]. 
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